NOTCH^IC expression is maintained in nonregressing Tet-o-MYC/MIT-NOTCH^IC tumors treated with Dox. (A) RT-PCR analysis of spleens from nonregressing Tet-o-MYC/MIT-NOTCH^IC tumors treated with Dox for the indicated times using the indicated specific primers. (B) Quantitative RT-PCR analysis on single-cell suspensions from spleens of nonregressing Tet-o-MYC/MIT-NOTCH^IC tumors treated with Dox. (C) Western blot analysis with antibodies against the indicated proteins in nonregressing Tet-o-MYC/MIT-NOTCH^IC tumors treated with Dox.